Overview
Day One Q2 2025 OJEMDA rev up 310% yr/yr to $33.6 mln
Company reports Q2 net loss of $30.3 mln
Ended Q2 with $453.1 mln in cash, cash equivalents, and investments
Outlook
Company expects full-year 2025 OJEMDA net product revenue of $140 mln to $150 mln
Result Drivers
OJEMDA SALES - OJEMDA net product revenue increased 310% yr/yr to $33.6 mln, driven by higher prescription volumes
PRESCRIPTION GROWTH - OJEMDA prescriptions exceeded 1,000 in Q2 2025, a 15% increase from Q1 2025
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.29
Q2 Net Income
-$30.32 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 73.1% above its August 4 closing price of $6.74
Press Release: ID:nGNX6y80Mx
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
